As Current Oncology (ISSN: 1718-7729) is of an open access format, you have free and unlimited access to the full text of all articles published in our journal. We welcome you to read our 2022 top highly cited papers in the Section “Genitourinary Oncology” shown below: 

1. “Current Advances in Immune Checkpoint Inhibition and Clinical Genomics in Upper Tract Urothelial Carcinoma: State of the Art”
by Gianluigi Califano, Idir Ouzaid, Paul Laine-Caroff, Arthur Peyrottes, Claudia Collà Ruvolo, Benjamin Pradère, Vincent Elalouf, Vincent Misrai, Jean-François Hermieu, Shahrokh F. Shariat et al.
Curr. Oncol. 2022, 29(2), 687–697; https://doi.org/10.3390/curroncol29020060
Available online: https://www.mdpi.com/1718-7729/29/2/60

2. “Nondetectable Prostate Carcinoma (pT0) after Radical Prostatectomy: A Narrative Review”
by Nikolaos Kalampokis, Nikolaos Grivas, Markos Karavitakis, Ioannis Leotsakos, Ioannis Katafigiotis, Marcio Covas Moschovas, Henk van der Poel and the European Association of Urology (EAU) Young Academic Urologists (YAU) Robotic Urology Working Group
Curr. Oncol. 2022, 29(3), 1309–1315; https://doi.org/10.3390/curroncol29030111
Available online: https://www.mdpi.com/1718-7729/29/3/111

3. “Clinical Benefit of Pembrolizumab in Advanced Urothelial Cancer Patients in Real-Life Setting: An Efficacy and Safety Monocentric Study”
by Elodie Dang, Alexandre Vallée, Coralie Lepage-Seydoux, Karine Sejean, Brigitte Bonan, Christine Abraham, Philippe Beuzeboc and Raffaele Ratta
Curr. Oncol. 2022, 29(2), 945–955; https://doi.org/10.3390/curroncol29020080
Available online: https://www.mdpi.com/1718-7729/29/2/80

4. “Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies”
by Ioannis A. Voutsadakis
Curr. Oncol. 2022, 29(3), 1390–1407; https://doi.org/10.3390/curroncol29030117
Available online: https://www.mdpi.com/1718-7729/29/3/117

5. “Trop-2 in Upper Tract Urothelial Carcinoma”
by Eisuke Tomiyama, Kazutoshi Fujita, Kosuke Nakano, Ken Kuwahara, Takafumi Minami, Taigo Kato, Koji Hatano, Atsunari Kawashima, Motohide Uemura, Tetsuya Takao et al.
Curr. Oncol. 2022, 29(6), 3911–3921; https://doi.org/10.3390/curroncol29060312
Available online: https://www.mdpi.com/1718-7729/29/6/312

6. “Diagnostic and Therapeutic Challenges in a Patient with Synchronous Very High-Risk Prostate Adenocarcinoma and Anal Carcinoma”
by Jonathan Wallach, Irini Youssef, Andrea Leaf and David Schwartz
Curr. Oncol. 2022, 29(1), 377–382; https://doi.org/10.3390/curroncol29010033
Available online: https://www.mdpi.com/1718-7729/29/1/33 

7. “Genomics and Immunomics in the Treatment of Urothelial Carcinoma”
by Veronica Mollica, Francesco Massari, Alessandro Rizzo, Roberto Ferrara, Arjun K. Menta and Jacob J. Adashek
Curr. Oncol. 2022, 29(5), 3499–3518; https://doi.org/10.3390/curroncol29050283
Available online: https://www.mdpi.com/1718-7729/29/5/283

8. “Next Wave of Targets in the Treatment of Advanced Renal Cell Carcinoma”
by Luisa M. Cardenas, Jasna E. Deluce, Shahrukh Khan, Omar Gulam, Saman Maleki Vareki, Ricardo Fernandes and Aly-Khan A. Lalani
Curr. Oncol. 2022, 29(8), 5426–5441; https://doi.org/10.3390/curroncol29080429
Available online: https://www.mdpi.com/1718-7729/29/8/429

9. “Clinical Lymph Node Involvement as a Predictor for Cancer-Specific Survival in Patients with Penile Squamous Cell Cancer”
by Makoto Kawase, Kimiaki Takagi, Kei Kawada, Takashi Ishida, Masayuki Tomioka, Torai Enomoto, Shota Fujimoto, Tomoki Taniguchi, Hiroki Ito, Koji Kameyama et al.
Curr. Oncol. 2022, 29(8), 5466–5474; https://doi.org/10.3390/curroncol29080432
Available online: https://www.mdpi.com/1718-7729/29/8/432

10. “The Role of Cytoreductive Nephrectomy in Renal Cell Carcinoma with Sarcomatoid Histology: A Case Series and Review of the Literature”
by Hana Studentova, Nikol Rusarova, Andrea Ondruskova, Anezka Zemankova, Vladimir Student Jr., Daniela Skanderova and Bohuslav Melichar
Curr. Oncol. 2022, 29(8), 5475–5488; https://doi.org/10.3390/curroncol29080433
Available online: https://www.mdpi.com/1718-7729/29/8/433